Lataa...
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis. Because checkpoints may also regulate autoreactivity, immune checkpoint inhibitor th...
Tallennettuna:
| Julkaisussa: | Rheumatology (Oxford) |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6900913/ https://ncbi.nlm.nih.gov/pubmed/31816080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kez308 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|